Consequently, this aberrant FoxO1 activation promotes the transcription of key gluconeogenic enzymes, such as phosphoenolpyruvate carboxykinase and glucose‐6‐phosphatase, exacerbating fasting hyperglycemia and insulin resistance in NAFLD [125]. This evidence concerns the gene FOXO1 and metabolic dysfunction-associated steatotic liver disease.